$クオイン・ファーマシューティカルズ(QNRX.US)$Stock has also fallen over 200% since last Monday is another reason they are ready to cover alomh with the borrow rate increasing from 81% to 315%. When they cover it will reach about 2.71.
6
2
報告
MDR81 :
I stuck at 1.5 average, I don't have much confident ER positive.. what is your advice @Mcsnacks H Tupack
$クオイン・ファーマシューティカルズ(QNRX.US)$ ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 4,062,500 ordinary shares represented by 4,062,500 American Depositary Shares (or pre-funded warrants in lieu thereof), Series D warrants to purchase an aggregate of up to 4,06...
2
報告
Dragana :
each share will come $1.60? no higher and no lower?
$クオイン・ファーマシューティカルズ(QNRX.US)$looks to be consolidating. I see blocks in the 1.30 range. That's likely where it'll go before it takes off. Then 🚀 to the 🌙!
1
3
報告
PortoCall :
I saw their share offering - what’s your input on that move? Wondering if I should take it or hold it.
Rockaphobicスレ主PortoCall:
ASHBURN, Va. - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a specialty pharmaceutical company, has announced the pricing of a public offering aimed at raising approximately $6.5 million. The offering includes 4,062,500 shares, each represented by American Depositary Shares (ADS), and warrants for purchasing additional shares. The combined purchase price for one ADS and associated Series D and Series E warrants is $1.60. These warrants, exercisable immediately upon issuance, are priced at $1.60 per share and will expire two and five years from the date of issuance, respectively. The company expects the offering to close on or about March 7, 2024, subject to standard closing conditions.
Rockaphobicスレ主 :
On March 13th, they'll be releasing their earnings report. My guess is that it will be all the fuel this will need to take a trip to the . Hope your are packed. The 14th will come fast.
Quoin Pharmaceuticals Receives FDA Clearance to Recruit Teenagers in Netherton Syndrome Clinical Trials. In a significant development that could potentially alter the trajectory of Netherton Syndrome treatment, Quoin Pharmaceuticals (NASDAQ: QNRX) has received clearance from the U.S. Food and Drug Administration (FDA) to include teenage subjects in their ongoing clinical studies. This decision is expected to broaden the ...
クオイン・ファーマシューティカルズに関するコメント
got to hold a dollar
Watch for shorts to cover shares today or tomorrow before ER
🚨 PUBLIC OFFERING 🚨
ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 4,062,500 ordinary shares represented by 4,062,500 American Depositary Shares (or pre-funded warrants in lieu thereof), Series D warrants to purchase an aggregate of up to 4,06...
Earnings tomorrow
let's hope that's the catalyst needed to get this back over 4
🚨 WATCHING 🚨
FDA approval and the price tanks
Medical Company Granted FDA Clearance For Netherton Syndrome Clinical Trials
In a significant development that could potentially alter the trajectory of Netherton Syndrome treatment, Quoin Pharmaceuticals (NASDAQ: QNRX) has received clearance from the U.S. Food and Drug Administration (FDA) to include teenage subjects in their ongoing clinical studies. This decision is expected to broaden the ...
back to 5 please
まだコメントはありません